We set realistic expectations up front, track real markers and measurements over time rather than just the scale, and adjust your plan based on how your body actually responds
Unlike full-length growth hormone, AOD-9604 selectively targets fat metabolism through beta-3 adrenergic receptor pathways without affecting insulin sensitivity or IGF-1 levels
The Clinical Evidence: What Trials Actually Showed Evaluating AOD-9604 before-and-after outcomes requires separating animal data from human data
The best option depends on your symptoms, lab results, and overall health
Animal studies have shown that when beta-3 adrenergic receptors were genetically removed, chronic AOD-9604 treatment produced no changes in weight or lipolysis, confirming the importance of this pathway
For the most effective dosage and administration method for your body, it is necessary to consult with a healthcare professional